Faron Pharmaceuticals, the Finnish clinical-stage drug developer, said on 4 November 2026 that five abstracts on its lead antibody bexmarilimab had been accepted for poster presentation at the 68th American Society of Hematology annual meeting, to be held in New Orleans from 12 to 15 December 2026. The abstracts include overall survival results from its BEXMAB study in higher-risk myelodysplastic syndrome, a form of blood cancer.

What the company does

Faron is based in Turku, Finland, and is listed on both AIM and Nasdaq First North in Helsinki. Its lead asset, bexmarilimab, is a humanised antibody that targets Clever-1, a receptor found on certain immune cells. The company is studying it in blood cancers and solid tumours, with its main focus on higher-risk myelodysplastic syndrome, known as HR-MDS.

Latest developments

Data due to be presented at ASH show that, in 20 evaluable frontline HR-MDS patients treated with bexmarilimab and azacitidine, the overall response rate was 85% and the complete remission rate was 45%, with a median duration of complete remission of 16.1 months. Median overall survival across that cohort was 12.1 months, and 8.8 months in patients with biallelic TP53 mutations. In 33 evaluable relapsed or refractory patients whose disease had progressed after hypomethylating agents, the response rate was 64% and median overall survival was 11.2 months. Faron said the safety profile appeared comparable to azacitidine alone.

Another abstract describes the design of BEXERA, a randomised, double-blind, placebo-controlled phase 2b trial in about 90 previously untreated HR-MDS patients at about 35 sites. Patients will receive one of two doses of bexmarilimab or placebo, each with azacitidine. Faron has said the trial is intended to select a dose for phase 3 and support future registration filings, and it announced a collaboration with Parexel in April 2026 to support it.

Financial and Dividend picture

Faron's half-year report, published on 26 August 2026, showed cash of €32.0m at 30 June 2026, up from €13.5m a year earlier, after a rights issue completed in April 2026 that raised €40.1m gross. The loss for the first half was €8.5m, compared with €19.3m a year earlier, and Research and Development spending was €7.6m. Borrowings were about €17.8m. In August, special rights were exercised for about €1.6m, linked to scheduled bond amortisation. The company does not pay a dividend and does not give a short-term outlook.

Sector and index context

Faron is an oncology-focused drug developer within the healthcare segment of the FTSE AIM All Share Index. Biotech valuations in this part of the market are highly sensitive to trial readouts and to funding conditions. A separate meta-analysis abstract, covering 61 cohorts and 5,034 patients, found pooled median overall survival of 6.68 months in arms enrolling only higher-risk MDS patients, which provides context for its own survival figures.

Key risks

The data so far come from relatively small, single-arm studies, and a randomised trial may not replicate them. Chief executive Juho Jalkanen has described the first half of 2026 as demanding. The company remains loss-making with significant borrowings, so further funding is likely to be needed before any approval. Competition in MDS treatment and regulatory requirements add further uncertainty.

What to watch next

The ASH posters in December, the start of patient enrolment in BEXERA, which was planned for the second half of 2026, and updates from investigator-initiated trials in solid tumours and acute myeloid leukaemia are the main near-term events. Investors will also watch cash use and any further financing.